Table 3. Pharmacokinetic parameters of the Chinese subjects after oral administration of 15 mg midazolam (mean±SD).
| PK parameter | Group 1 (Age 20–50 years) |
Group 2 (Age 51–65 years) |
Group 3 (Age 66–75 years) |
Group 4 (Age >76 years) |
||||
|---|---|---|---|---|---|---|---|---|
| Male (n=5) | Female (n=5) | Male (n=5) | Female (n=5) | Male (n=5) | Female (n=5) | Male (n=5) | Female (n=5) | |
| Cmax (ng/mL)a | 68.6±17.5 | 88.4±25.3 | 100.3±29.5 | 95.7±25.1 | 80.5±18.5 | 115.4±52.6 | 100.7±69.3 | 92.9±51.0 |
| Tmax (median, range) | 1 (0.5–1.5) | 0.5 (0.25–0.5) | 0.5 (0.5–0.5) | 0.5 (0.25–3) | 0.5 (0.5–1.5) | 0.5 (0.25–0.5) | 0.5 (0.25–0.5) | 0.5 (0.25–4) |
| T1/2 (h) | 2.9±0.9 | 3.6±1.0 | 3.7±0.6 | 6.1±0.9 | 4.7±1.3 | 4.8±1.9 | 3.8±0.9 | 4.4±1.3 |
| AUC0-∞(h·ng/mL) | 223.8±52.5 | 199.3±55.6 | 274.3±123.4 | 278.0±167.0 | 195.7±74.8 | 262.2±42.9 | 233.8±77.8 | 274.2±100.3 |
| CL/F (L/h) | 70.0±16.0 | 80.7±24.8 | 63.1±24.7 | 66.7±28.9 | 84.8±28.4 | 64.3±20.4 | 70.1±22.9 | 61.9±25.4 |
| V/F (L) | 306.4±149.6 | 398.7±86.6 | 326.2±107.7 | 568.9±194.3 | 559.7±238.6 | 387.2±102.5 | 382.6±172.5 | 387.6±172.6 |
aP>0.05.